Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05413421
Phase: Phase 1
Trial Summary: The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metast – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ORIC Pharmaceuticals
Acronym:

Pin It on Pinterest